Ionis drops after forecasting 2026 revenue below expectations
25/02/2026 12:37
** Shares of drugmaker Ionis Pharmaceuticals IONS.O fall 6.4% to $80 premarket ** Co forecasts 2026 revenue between $800 million and $825 million, below analysts' average expectation of $902 million ** IONS' genetic disorder drug Tryngolza generated $50 million in sales in Q4, a 56% increase over the prior quarter ** Co reports Q4 loss of $1.41/shr vs analysts' average loss estimate of $1.32/shr ** IONS' quarterly revenue of $203 million beats analysts' estimate of $156.1 million ** Up to last close, stock up 8% YTD (Reporting by Christy Santhosh) ((Christy.Santhosh@thomsonreuters.com))
Recent news on Ionis Pharmaceuticals
See all newsAnalysis: US prices for new drugs fell in 2025 as fewer costly gene therapies were launched
Brief: Ionis Announces License Agreement With Recordati For Zilganersen In Alexander Disease (Axd) In All Countries Outside The U.S.
Brief: Ionis Pharmaceuticals Says FDA Approved Tryngolza For Severe Hypertriglyceridemia
Brief: FDA Approves Treatment To Reduce Risk Of Acute Pancreatitis In Adults With Severe Hypertriglyceridemia
Brief: Ionis Announces Appointment Of Ludwig Hantson, Ph.D. To Board Of Directors